New Report – Telemedicine Market in Brazil, Russia, India, China (BRIC) – Advanced Technologies, Global Forecast by MarketsandMarkets

DALLAS, August 18, 2010 – According to the new market research report, "Telemedicine Market in
Brazil, Russia, India, China (BRIC) – Advanced technologies, Global Forecast"
published by MarketsandMarkets (www.marketsandmarkets.com), the BRIC
telemedicine is expected to reach a market size of $418.4 million by the year
2014, at a CAGR of 15.8% from 2009-2014. The BRIC telemedicine technology
market is [...]

Medical Errors Driving the Need to Build a Safer Health System – Frost & Sullivan Web Conference

LONDON, August 18, 2010 – Substantial increases in healthcare expenditure over the last decade have
motivated governments and healthcare organisations to identify and eliminate
unnecessary costs. According to recent research, medical errors are one of
the foremost perpetrators of high expenses, increasingly overwhelming and
burdening the health system. In order to alleviate these needless mistakes,
most manufacturers and governments [...]

Ethicon Endo-Surgery Introduces HARMONIC ACE(R) 45 cm Curved Shears Designed For Extended Reach in Obese Patients

NORDERSTEDT, Germany, August 18, 2010 – Ethicon Endo-Surgery (EES), has announced the introduction of a new
addition to its HARMONIC(R) line of surgical devices, the HARMONIC ACE(R) 45
cm Curved Shears.

HARMONIC ACE(R) 45 cm, designed to extend the reach of surgeons for
minimally invasive procedures involving obese patients, is 25 percent longer
(or 9cm) [...]

Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human

FREMONT, California, August 18, 2010 – Quark Pharmaceuticals, Inc., a world leader in the discovery and
development of RNAi-based therapeutics, today announced that it has granted
Novartis an option to obtain an exclusive worldwide license to develop and
commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the
subject of a Phase II clinical trial.

[...]

Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville

Lonza to Provide Exclusive Manufacturing Services to Regenicin for new Proprietary Skin Production Technology

NEW YORK, August 18, 2010 – Regenicin, Inc. (OTC Bulletin Board: WDSTD), a development stage
biotechnology company, announced today that it has completed an initial
US$3.25 million funding in conjunction with its acquisition of a worldwide
exclusive license to know-how technology controlled by Lonza [...]

New Report – Bioinformatics Market – Advanced Technologies, Global Forecast and Winning Imperatives (2009 – 2014) By MarketsandMarkets

DALLAS, August 18, 2010 – According to the new market research report "Bioinformatics Market -
Advanced Technologies, Global Forecast and Winning Imperatives (2009-2014)",
published by MarketsandMarkets (www.marketsandmarkets.com), the global
bioinformatics market is expected to reach a $8.3 billion by 2014 at a high
CAGR of 24.8% from 2009-2014. While knowledge management formed the largest
submarket is 2009 at $1.3 [...]